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Abstract: The use of tumour necrosis factor (TNF) antagonists (infliximab [IFN], etanercept [ETN], adalimumab [ADA]) 
has changed the course of many rheumatic diseases, including rheumatoid arthritis (RA). However, some questions 
concerning their safety have emerged since their approval because they can trigger immunisation, induce rare type I and 
III hypersensitivity, and cause acute and delayed reactions. The aim of this study was to evaluate the correlations between 
hypersensitivity reactions to biological agents, disease activity and the development of class-specific IgA and IgM 
antibodies against the three anti-TNF agents in patients with RA. 
This longitudinal observational study involved consecutive outpatients with active RA who started treatment with IFN 
(n=30), ETN (n=41) or ADA (n=28). Clinical data and systemic and local side effects were collected prospectively at 
baseline and after six months of anti-TNF treatment. Serum samples were taken at the same time points in order to 
measure antibodies against the TNF blockers, anti-nuclear (ANA) and anti-dsDNA antibodies. The IgA and IgM 
antibodies specific to all three anti-TNF- agents were analysed using ImmunoCaP Phadia- Thermofisher especially 
developed in collaboration with the laboratory of Immunology and Allergy, San Giovanni di Dio, Florence. 
The mean age of the 99 patients (86% females) was 54.6±12.4 years, and the median disease duration was 11.2±.3.2 years 
(range 3-14.3). The three treatment groups were comparable in terms of age, gender, rheumatoid factor and anti-
citrullinated peptide (CCP) antibody positivity, and baseline C-reactive protein levels, erythrocyte sedimentation rate, 28-
joint disease activity scores, and concomitant medications. Twelve patients treated with INF (40%) had anti-IFN IgM, and 
two (6%) anti-IFN IgA; 19 patients treated with ADA (68%) had anti-ADA IgM, and four (6%) anti-ADA IgA; and 27 
patients treated with ETN (66%) had anti-ETN IgM, and 24 (58%) anti-ETN IgA. There were five systemic reactions in 
the IFN group, and seven adverse local reactions in both the ADA and the ETN group. There was no correlation between 
drug-specific IgA and IgM antibodies (p=0.65). There was also no correlation between the antibodies and disease activity 
after six months of treatment (r=0.189;p=0.32). 
Our findings show that the development of antibodies against IFN, ADA or ETN of IgA and IgM class are not related to 
any decrease in efficacy or early discontinuation of anti-TNF treatment in RA patients, nor to systemic and local 
reactions. Further studies of larger series of RA patients are needed to confirm the relationships between the development 
of drug-specific antibodies, serum TNF blocker levels, and disease activity. 
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INTRODUCTION 
 More than 400,000 patients throughout the world have 
been treated with anti-tumour necrosis factor (TNF) drugs  
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 (infliximab [IFN], etanercept [ETN], adalimumab [ADA]) 
because of rheumatoid arthritis (RA), psoriatic arthritis (PA) 
and seronegative spondyloarthritis. However, some 
questions concerning their safety have emerged since their 
approval because they can trigger immunisation, induce rare 
type I and III hypersensitivity, and cause acute and delayed 
reactions [1]. 
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 There have been many reports of reactions in patients 
receiving intravenous IFN, a chimeric IgG1K anti-TNF 
agent [2], and immune-mediated side effects such as various 
cutaneous reactions have been encountered during therapy 
subcutaneous anti-TNF drugs. One recent paper has 
described injection site reactions in 29.3% patients treated 
with ETN [3]. The adverse reactions to biological agents 
have been categorised into five types, including a 
complemented-mediated reaction with immediate IgE or 
delayed IgG antibody formation [4]. 
 Biological therapeutic agents may be recognised by the 
human immune system as ‘non-self’ and induce an immune 
response (also known as immunogenicity). Endogenous 
therapeutic proteins such as erythropoietin and growth factors 
have amino acid sequences that are identical to those of the 
human equivalent and can be immunogenic as a result of 
glycosylation or conformational changes that expose new 
epitopes. Therapeutic antibodies carry unique complementarity 
determining regions that contain stretches of sequences that are 
frequently recognised as foreign and induce the formation of 
anti-drug antibodies. This has clinical implications insofar as it 
can lead to adverse events, the most common of which are 
infusion reactions associated with a decrease in drug activity. A 
number of studies have shown that these antibodies play a role 
in the development of immunogenicity, but only a few have 
investigated the correlations between the different isotypes of 
immunoglobulin (Ig) and disease activity. 
 The aim of this study was to evaluate the correlations 
between hypersensitivity reactions to biological agents, 
disease activity and the development of class-specific IgA 
and IgM antibodies against the three TNF blockers. 
METHODS 
 We evaluated 99 RA patients (30 treated with IFN, 28 
with ADA, and 41 with ETN) with a mean age of 54.6±12.4 
years and a median disease duration of 11.2±.3.2 years 
(range 3-14.3). Eighty-six percent were females. The three 
treatment groups were comparable in terms of age, gender, 
rheumatoid factor (RF) and anti-citrullinated peptide (CCP) 
antibody positivity, and baseline C-reactive protein (CRP) 
levels, erythrocyte sedimentation rate (ESR), 28-joint disease 
activity scores (DAS-28), and concomitant medications 
(Table 1). 
 DAS28 and the number of local and systemic adverse 
reactions were evaluated at baseline and after six months of 
treatment, and drug-specific IgA and IgM antibodies were 
measured using ImmunoCaP Phadia- Thermofisher 
especially developed in collaboration with the laboratory of 
Immunology and Allergy, San Giovanni di Dio, Florence. 
The technology of ImmunoCaP is based on an extremely 
high total binding capacity per mg of cellulose combined 
with an optimal amount of cellulose in each solid phase, and 
ensures the binding of all relevant antibodies, regardless of 
antibody affinity, while still showing low non-specific 
binding levels. The ImmunoCAP solid phase consists of a 
cellulose derivative enclosed in a capsule, and the 
hydrophilic, highly branched polymer provides an ideal 
microenvironment in which allergens are irreversibly bound 
while maintaining their native structure. Anti-nuclear 
antibodies (ANAs) and anti-double-stranded DNA (dsDNA) 
antibodies were measured at the same times. 
Statistical Analysis 
 The descriptive data are shown as mean values + 
standard deviations (SD), and were compared using 
Student’s t test. The correlations were assessed by means of 
Pearson’s correlation coefficient. All of the tests were two-
sided and a P value of <0.05 was considered statistically 
significant. The analyses were made using SPSS statistical 
software (version 14.0) and StatXact-7 (version 7, Cytel 
Software Corporation, Cambridge, MA). 
RESULTS 
 After six months, 12 of the 30 patients treated with IFN 
(40%) had anti-IFN IgM, and two (6%) anti-IFN IgA; 19 of 
the 28 patients treated with ADA (68%) had anti-ADA IgM, 
and four (6%) anti-ADA IgA; and 27 of the 41 patients 
treated with ETN (66%) had anti-ETN IgM, and 24 (58%) 
anti-ETN IgA. 
 There were five systemic reactions in the IFN group, and 
seven adverse local reactions in both the ADA and the ETN 
group. There was no correlation between the drug-specific 
IgA and IgM antibodies (p=0.65), and no correlation 
between drug-specific antibodies and the development of 
adverse events (p=0.99). 
 
Table 1. Characteristics of Patients Included in the Study 
 
 INFLIXIMAB 30 pts ADALIMUMAB 28 pt ETANERCEPT 41 pt 
Age (yrs SD) 52.3±12.2 53.6±11.8 54.5±12.9 
Disease duration (yrs SD) 10.3±2.8 11.5±3.1 11.8±2.9 
Rheumatoid factor positivity 76% 78% 75% 
Anti-CCP positivity  81% 79% 78% 
ESR mm/h 54.3±8.4 55.7±7.2 53.5±6.7 
CRP mg/dl 3.2±1.7 3.4±1.5 3.7±1.4 
DAS28 5.46±2.1 5.43±1.9 5.38±1.8 
Corticosteroids dose mg/day  6.1±1.2 6.4±1.1 6.3±1.2 
Methotrexate dose mg/week  12.5±2.2 12.1±2.1 11.9±2.4 
SD= standard deviation; ERS= erythrocyte sedimentation rate; CRP= C-reactive protein. 
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 There was also no correlation between the antibodies and 
disease activity after six months of treatment (r=0.189; 
p=0.32) (Figs. 1-4). 
DISCUSSION 
 Our findings show that the presence of drug-specific IgM 
and IgA antibodies in patients with RA does not correlate 
Fig. (1). Correlation between IgA and IgM anti Drugs and Adverse Reactions. 
Fig. (2). Correlation between IgA and IgM anti Infliximab and DAS28. 
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with systemic or local site reactions or disease activity. 
 Class-specific anti-drug antibodies can be involved in 
adverse reactions during the treatment of RA, and various 
findings concerning adverse reactions, disease activity and 
the development of class- specific anti-drug antibodies have 
been described. The reactions have been related to IFN 
immunogenicity and the development of various antibodies. 
 A paper evaluated the development of IgE and non-IgE 
anti-IFN antibodies, and their relationship with infusion 
reactions in 71 patients (11 reactive, 11 therapeutic non-
responders, and 49 unreactive therapeutic responders) using 
the ImmunoCAP assay for IgE and an ELISA assay for IgM 
and non-isotype-specific anti-IFN antibodies [5]. Eleven of 
the 71 patients experienced a hypersensitivity reaction to 
IFN; non-isotype-specific anti-IFN antibodies were detected 
in eight reactive and two non-responding patients; and three 
patients with severe reactions had anti-IFN IgE antibodies 
and positive skin tests. Detectable levels of anti-IFN IgM 
antibodies were found in three additional patients with 
negative IgE and skin test results. Anti-IFN IgE and IgM 
antibodies were not detectable in the two non-responding 
patients [5]. In another our paper published we didn’t 
observe a correlation between atopy and hypersensitivity 
reactions during therapy with three different TNF- blocking 
agents in rheumatoid arthritis [6]. 
 A further study has evaluated disease activity, serum 
ADA concentrations and anti-ADA antibodies at baseline 
 
Fig. (3). Correlation between IgA and IgM anti Adalimumab and DAS28. 
 
Fig. (4). Correlation between IgA and IgM anti Etanercept and DAS28. 
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and at eight time points over a period of 156 weeks, and also 
compared treatment discontinuations, minimal disease 
activity and clinical remission between the patients with and 
without anti-ADA antibodies. The results showed that the 
development of anti-drug antibodies is associated with the 
negative outcome of ADA treatment in RA patients: the 
patients with anti-ADA antibodies not only discontinued 
treatment more often and earlier than those without, but also 
showed greater disease activity during treatment and only 
rarely achieved clinical remission. The study also found that 
two-thirds of the anti-ADA antibody-positive patients 
developed the antibodies during the first 28 weeks of 
treatment, and that their presence substantially influenced 
serum ADA concentrations [7]. 
 Two studies of patients switching TNF inhibitors have 
shown that the reason for the absence of a response to a first 
anti-TNF drug has implications on responses to a second 
inhibitor. In the patients who developed anti-drug antibodies 
against the first drug (IFN or ADA), the response to the 
second TNF inhibitor (ADA or ETN) was no different from 
that of TNF-naive patients, whereas the patients who did not 
respond to the first TNF inhibitor despite adequate serum 
drug levels and the absence of anti-drug antibodies had a 
significantly worse response to the second inhibitor than 
both the TNF-naive patients and the patients with anti-drug 
antibodies to their first TNF inhibitor [8,9]. 
 Why do some patients develop an anti-drug antibody 
response while others do not? It is known that the use of 
concomitant immunosuppressants is associated with a lower 
frequency of anti-drug antibodies [10,11] and, in some 
studies, the presence of anti-drug antibodies has been 
associated with decreased serum drug levels and a 
diminished response [12,13]. Furthermore, in some cases, 
the combined presence of anti-drug antibodies and 
therapeutic monoclonal antibody (TmAb) concentrations 
leads to the formation of immune complexes, and their 
continuous presence in serum leads to adverse events. Little 
is known about the safety of TmAb and anti-TmAb antibody 
immune complexes, but the presence of antibodies anti-IFN 
and immune complexes of various sizes may be associated 
with infusion-related hypersensitivity reactions [7,14]. 
 Various classes of immunoglobulins with different 
affinities can be produced. Moreover, the presence of anti-
drug antibodies fluctuates over time; immunological 
tolerance develops at a certain time during treatment and so 
the timing of blood sampling can affect the detection of 
immunogenicity. There are a number of assay formats for the 
detection of anti-drug antibodies [15], but none of the 
available assays can detect all of the subclasses or idiotypes. 
The avidity of IgM antibodies is low, and they are therefore 
difficult to detect, whereas affinity-matured IgG1 and IgG4 
antibodies are easier to detect. IgE can also be highly avid, 
but excess IgG makes it difficult to detect the relatively low 
amounts of IgE. The most widely used assays include direct 
enzyme-linked immunosorbent assays (ELISAs), which are 
straightforward but affected by non-specific binding [15,16]. 
Two-site or bridging assays are sensitive and specific, but do 
not detect IgG4 antibodies and are susceptible to drug 
interference, and antigen binding tests (ABTs) are specific  
 
 
and less susceptible to drug interference; however, both 
radio-immunoassays require a laboratory equipped to deal 
with radioactivity. A fourth type are cell-based assays which 
are not used frequently for immunogenicity testing, because 
they are time consuming, complex and unreliable [17]. 
 Therapeutic antibodies are removed from the circulation 
similarly or slightly more rapidly than endogenous IgG. The 
production of anti-drug antibodies can accelerate clearance 
because of the formation of immune complexes that are 
taken up by the liver and spleen. Furthermore, drug and anti-
drug antibody complexes are not biologically active if the 
anti-drug antibodies are directed to the antigen-binding site, 
which is usually the only foreign part of humanised or fully 
human therapeutic antibodies. These two mechanisms 
decrease drug levels and consequently impair treatment 
responses [18]. 
 One important limitation of our study is the absence of a 
record of drug levels. A recent longitudinal, observational 
cohort of RA patients treated with IFN for at least six 
months assessed treatment intervals, DAS28, trough IFN 
levels and anti-IFN antibody levels, and found low (and 
high) IFN serum trough levels are prevalent, interestingly 
also in patients with low disease activity. Consecutive 
measurements of serum trough levels and anti-IFN 
antibodies are reliable in stable patients [19]. 
 The different types of immunoglobulin (IgA and IgM-
ADA), different clearance due to the formation of immune 
complexes, and the probable absence of anti-drug antibodies 
with neutralising effects [20] may explain the lack of a 
correlation between the development of anti-drug antibodies, 
systemic or local reactions and disease activity. 
 In many other papers a different percentage of ADA in 
different diseases was observed. A recent review showed a 
different percentage of ADA to Infliximab, Adalimumab, 
Etanercept in spondiloarthritis, psoriatic arthritis and 
Crohn’s Disease, the value could be influenced also by 
immunosoppressive therapy such as Methotrexate. Moreover 
in rheumatoid arthritis patients the detection of ADA is 
counfounded by the presence of Rheumatoid Factor that can 
mask the epitopes bound in these assay [21]. 
CONCLUSIONS 
 Our findings indicate that the development IFN, ADA or 
ETN antibodies of IgA and IgM class are not related to a 
decrease in efficacy or the early discontinuation of anti-TNF 
treatment in RA patients, and that there is no correlation 
between systemic and local reactions and antibody 
formation. Further studies of larger series of RA patients are 
needed to confirm the relationship between the development 
of drug-specific antibodies, serum TNF blocker levels, and 
disease activity. 
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